GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kite Pharma Inc (NAS:KITE) » Definitions » Net Debt Paydown Yield %

Kite Pharma (Kite Pharma) Net Debt Paydown Yield % : 0% (As of May. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Kite Pharma Net Debt Paydown Yield %?

Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt. As of today, Kite Pharma's Net Debt Paydown Yield % was 0%.


Kite Pharma Net Debt Paydown Yield % Historical Data

The historical data trend for Kite Pharma's Net Debt Paydown Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kite Pharma Net Debt Paydown Yield % Chart

Kite Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16
Net Debt Paydown Yield %
- - - - -

Kite Pharma Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Net Debt Paydown Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kite Pharma's Net Debt Paydown Yield %

For the Biotechnology subindustry, Kite Pharma's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kite Pharma's Net Debt Paydown Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kite Pharma's Net Debt Paydown Yield % distribution charts can be found below:

* The bar in red indicates where Kite Pharma's Net Debt Paydown Yield % falls into.



Kite Pharma Net Debt Paydown Yield % Calculation

Kite Pharma's Net Debt Paydown Yield % for the quarter that ended in Jun. 2017 is calculated as:

Net Debt Paydown Yield %
=( TTM Average Debt   (1-Year Ago))-TTM Average Debt )/Market Cap
=( - )/5917.307361
=0 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Kite Pharma  (NAS:KITE) Net Debt Paydown Yield % Explanation

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.

In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.

We calculating the TTM average debt by adding up the total debt, calculated by the sum of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation, in the trailing twelve months(TTM) divided by the counts of the total debt, accoring to the company's report frequency.


Kite Pharma Net Debt Paydown Yield % Related Terms

Thank you for viewing the detailed overview of Kite Pharma's Net Debt Paydown Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kite Pharma (Kite Pharma) Business Description

Traded in Other Exchanges
N/A
Address
Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products. In partnership with the National Cancer Institute through a cooperative research and development agreement, Kite is advancing a pipeline of proprietary product candidates, both chimeric antigen receptor and T-cell receptor products, targeting a wide range of cancer indications. The company also has a strategic collaboration with Amgen to develop and commercialize next-generation CAR-T therapies.
Executives
Jonathan M Peacock director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
David Bonderman director 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Franz B Humer director 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
Shawn Tomasello officer: Chief Commercial Officer C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Ian T Clark director SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Farah Champsi director ONE EMBARCADERO CENTER SUITE 3700, SAN FRANCISCO CA 94111
Helen Susan Kim officer: EVP, Business Development 3832 BAY CENTER PLACE, HAYWARD CA 94545
Timothy L. Moore officer: EVP, Technical Operations C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Ran Nussbaum director C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Cynthia M Butitta officer: Chief Operating Officer 3165 PORTER DRIVE, PALO ALTO CA 94304
Owen N. Witte director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
David D Chang officer: EVP, R&D, Chief Medical Off. C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Joshua A Kazam director 689 5TH AVENUE, 12TH FLOOR, NEW YORK NY 10022
Arie Belldegrun director, officer: Chairman, President and CEO UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738
Margo R Roberts officer: Chief Scientific Officer 2225 COLORADO AVENUE, SANTA MONICA CA 90404

Kite Pharma (Kite Pharma) Headlines

From GuruFocus

Mario Gabelli's Top 5 New Buys for the 3rd Quarter

By Sydnee Gatewood Sydnee Gatewood 11-03-2017

Multiple Companies Achieve Yearly Highs

By yifan900 yifan900 10-03-2017

Andreas Halvorsen Nearly Quadruples Stake in Kite Pharma

By David Goodloe David Goodloe 10-06-2015

Mario Gabelli Exits Kite Pharma, Trims Time Warner

By Tiziano Frateschi Tiziano Frateschi 02-07-2018